Another Imaginary World: The ICER Claims for the Long-Term Cost-Effectiveness and Pricing of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors in Tardive Dyskinesia

Another Imaginary World: The ICER Claims for the Long-Term Cost-Effectiveness and Pricing of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors in Tardive Dyskinesia

The recently released value assessment of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia by the Institute for Clinical and Economic Review (ICER) relies upon a long-term modeling exercise to support recommendations for what the ICER sees as the appropriate pricing for th...

Full description

Bibliographic Details
Main Author: Paul C. Langley
Format: Article
Language:English
Published: University of Minnesota Libraries Publishing 2017-10-01
Series:INNOVATIONS in Pharmacy
Subjects:
ICER
VMAT2 inhibitors
value assessments
pseudoscience
limited evidence
credible claims
Online Access:https://pubs.lib.umn.edu/index.php/innovations/article/view/927

Internet

https://pubs.lib.umn.edu/index.php/innovations/article/view/927

Similar Items